Prosonix has announced that a consortium of inhaled medicine and respiratory disease researchers with funding from the Biomedical Catalyst “has confirmed the potential of its Multi-component Particle (MCP) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases.”
The research project included in vitro and ex vivo testing as well as the development of biological models and investigation of issues related to manufacturability.
Prosonix CEO David Hipkiss commented, “We are delighted that the outcome of the Biomedical Catalyst program has confirmed the potential of our MCP Technology as a basis for the development of cost-effective fixed dose combination therapies for respiratory diseases. Such combinations, in particular triple FDCs, are expected to become the mainstay of therapy in a large proportion of COPD patients over the coming years as they are anticipated to have important clinical, patient and payer benefits, being more convenient and more cost-effective than the current standard of care, which involves taking multiple medications from separate, often diverse, devices. We thank our collaborators for their valuable contributions to this project and we look forward to selecting candidates for formal development studies over the coming months.”
The MCP technology allows for creation of API-only fixed dose combination MDI and DPI formulations where the active drugs are combined in a set ratio within each single particle. Prosonix has tested ICS/LAMA, LABA/LAMA and LABA/LAMA/ICS combinations based on the MCP technology and says that it will advance at least one of those candidates into formal development within months.
Researchers participating in the consortium included Rob Price of the University of Bath, Peter Barnes and Omar Usmani of Imperial College London, and Ben Forbes of King’s College London.
Earlier this month, Prosonix filed an MAA for its PSX1001 generic fluticasone propionate inhaler.
Read the Prosonix press release.
